MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.41
+0.24
+1.58%
Closed 16:00 08/13 EDT
OPEN
15.23
PREV CLOSE
15.17
HIGH
15.87
LOW
15.11
VOLUME
48.71K
TURNOVER
--
52 WEEK HIGH
32.40
52 WEEK LOW
6.74
MARKET CAP
127.79M
P/E (TTM)
-1.9041
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LUMO stock price target is 28.33 with a high estimate of 34.00 and a low estimate of 18.00.

EPS

LUMO News

More
Lumos Pharma Q2 EPS $(0.65) Up From $(2.47) YoY, Sales $33.00K
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.65) per share. This is a 73.68 percent increase over losses of $(2.47) per share from the same period last year. The company reported $33.00 thousand in sales
Benzinga · 12h ago
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 20h ago
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close
GlobeNewswire · 07/28 20:01
Lumos Pharma shares are trading higher after the company announced the sale of its Priority Review Voucher for $100 million. UPDATE: Shares have since reversed, now lower.
Benzinga · 07/28 14:01
TCOM, PII among premarket gainers
Seeking Alpha · 07/28 12:16
SPPI, TESS, CRMD and ADMS among after-hours movers
Seeking Alpha · 07/27 21:45
Lumos rises on sale of its priority voucher rights for $60M
Seeking Alpha · 07/27 21:12
Lumos Pharma shares are trading higher after the company announced the sale of its Priority Review Voucher for $100 million.
Benzinga · 07/27 20:08

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About LUMO

Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
More

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.